Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Laboratorio integrado de medicina especializada(LIME) | UNKNOWN |
| Proyecto de regalias BPIN 2020000100152 | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Recent research evidence shows that levels of antibodies acquierd post vacunation against SARS-Cov-2 decrease over time as well as the efficacy to control the infection, additionally in a multicenter study carried out in 2020 were evidenced differences in the time it took to decrease the antibodies according to the type of vaccine, defined as mRNA or other types of vaccine.
In this study , the variation of the SARS-Cov-2 antibody levels in patients from Valle de Aburrá will be correlated according to the COVID-19 vaccine received.
After being informed about the study, all patients giving written informed consent will undergo a serial IgM -IgG COVID-19 antibodies blood test and SARS-Cov-2 PCR by nasopharingeal swab, that will be taken at the beginning of the study and mensually for two months.
During the study will be done an active search for SARS-CoV-2 infections in the vaccinated people cohort, and if it is posible to characterize the variant of SARS-CoV-2 in participants previously vaccinated against this pathogen.
The main objective of this study is to describe the pattern of antibodies blood test based in the type of vaccine and correlated the pattern of antibodies SARS-Cov-2 levels in a population of Valle de Aburrá.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Early vaccinated against COVID-19 | 80 subjects with less than 4 months after being fully vaccinated against COVID-19 |
| |
| Late vaccinated against COVID-19 | 80 subjects with more than 4 months after being fully vaccinated against COVID-19 |
| |
| COVID-19 infection | 40 patients diagnostic of COVID-19 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Levels of IgG and IgM SARS-CoV-2 antibodies blood test. | Diagnostic Test | 0,1,2 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| IgG and IgM antibodies blood test levels generated by the different COVID-19 vaccines in people throughout the time of the study. | Through study completion, an average of 2 months |
| Measure | Description | Time Frame |
|---|---|---|
| Comparing immunoglobulins M and G levels in vaccinated patients against SARS-CoV-2 with RNA and non RNA vaccines. | Through study completion, an average of 2 months | |
| SARS-CoV-2 infections in vaccinated patients against COVID-19. | Through study completion, an average of 2 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
People with a fully vaccination scheme for COVID-19 according to the Ministerio de Salud y ProtecciĂłn Social de Colombia and patients diagnosed with SARS-CoV-2 infection in the last 60 days, without matter vaccination status against SARS-CoV-2.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ivone Jimenez | Contact | +57 (4) 2196022 | ivone.jimenez@udea.edu.co |
| Name | Affiliation | Role |
|---|---|---|
| Andres F Zuluaga, MD, MSc, MeH | Universidad de Antioquia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Laboratorio Integrado de Medicina Especializada | Recruiting | MedellĂn | Antioquia | 050022 | Colombia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| RT-PCR SARS-CoV-2 nasopharyngeal swab | Diagnostic Test | 0,1,2 months |
|
| Correlate through time immunoglobulins M and G levels in people vaccinated against COVID-19 and SARS-CoV-2 acute infected patients. | Through study completion, an average of 2 months |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |